INmune Bio, Inc. (NASDAQ:INMB) Receives Average Recommendation of “Hold” from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.00.

A number of equities analysts have commented on INMB shares. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

INmune Bio Stock Performance

Shares of INmune Bio stock opened at $1.23 on Thursday. The company has a market cap of $32.69 million, a P/E ratio of -0.65 and a beta of 0.88. INmune Bio has a one year low of $1.09 and a one year high of $11.64. The firm has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.62.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. As a group, equities analysts predict that INmune Bio will post -2.24 earnings per share for the current year.

Institutional Trading of INmune Bio

Hedge funds have recently modified their holdings of the business. Intech Investment Management LLC acquired a new stake in shares of INmune Bio in the 2nd quarter valued at approximately $26,000. Cary Street Partners Financial LLC acquired a new stake in shares of INmune Bio in the 3rd quarter valued at approximately $29,000. Independent Advisor Alliance acquired a new stake in shares of INmune Bio in the 3rd quarter valued at approximately $30,000. Squarepoint Ops LLC acquired a new stake in shares of INmune Bio in the 3rd quarter valued at approximately $30,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of INmune Bio in the 4th quarter valued at approximately $26,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.